VirtualScopics' Chief Financial Officer to Resign
Ms. Henderson Relocating to Europe
ROCHESTER, N.Y., June 14, 2013
ROCHESTER, N.Y., June 14, 2013 /PRNewswire/ --VirtualScopics, Inc.
(NASDAQ:VSCP), a leading provider of quantitative imaging, today announced
that on June 12, 2013 Molly Henderson, its Chief Business and Financial
Officer, Sr. Vice President notified the company of her intention to resign
from the company effective August 31^st, 2013 due to the relocation of her
family to Europe. Ms. Henderson will continue in her current role until
August 31, 2013.
Jeff Markin, President and Chief Executive Officer of VirtualScopics stated,
"Molly has made a significant impact on the company and our employees during
her greater than 10 years with the organization. During her tenure the
company has achieved revenue growth in excess of 500% while moving from a cash
consuming privately held organization to one that is a publicly traded company
listed on NASDAQ. Molly was a key driver of these achievements." He added,
"On a more personal note Molly has been a true partner of mine in leading the
company through some very exciting as well as challenging times and was the
initial architect of our strategy to expand into personalized medicine. We
thank her for her leadership and wish her and her family well as they embark
on their relocation to Europe."
Further, Robert Klimasewski, Chairman of the Board of VirtualScopics stated,
"Molly is a very talented executive who has made significant contributions to
the company. The board has relied on her judgments and insights in making
important decisions. We wish her well in her next endeavors."
The company has initiated a search for a new Chief Financial Officer.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate
drug and medical device development. VirtualScopics has developed a robust
software platform for analysis and modeling of both structural and functional
medical images. In combination with VirtualScopics' industry-leading
experience and expertise in advanced imaging biomarker measurement, this
platform provides a uniquely clear window into the biological activity of
drugs and devices in clinical trial patients, allowing sponsors to make better
decisions faster. For more information about VirtualScopics, visit
CONTACTS: Investor Relations: Company
The Shoreham Group President
80 Eighth Ave, Ste 1107 500 Linden
New York, NY 10011 New York
+1 212 242 7777 Direct +1 585
SOURCE VirtualScopics, Inc.
Press spacebar to pause and continue. Press esc to stop.